Kimberly-Clark to Acquire Kenvue in $48.7 Billion Deal
Kimberly-Clark (KMB) announces acquisition of Kenvue (KVUE) for $48.7 billion, creating a global health and wellness powerhouse with 10 billion-dollar brands serving consumers worldwide.
Kimberly-Clark (KMB) announces acquisition of Kenvue (KVUE) for $48.7 billion, creating a global health and wellness powerhouse with 10 billion-dollar brands serving consumers worldwide.
J&J is spinning off its slower-growing $9.2B DePuy Synthes joint replacement business to focus on high-profit drugs and handle US price demands.
Activist investor Starboard Value takes position in Keurig Dr Pepper after its €15.7B JDE Peet's acquisition announcement triggered 25% stock decline and investor concerns.
Trump officials will warn pregnant women that Tylenol (acetaminophen) may cause autism and suggest a drug called leucovorin for treatment. Tylenol's maker and many doctors reject this claim, citing over a decade of research showing no credible link.